F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review
详细信息 查看全文
- 作者：Milly A Schr?er-Günther (1)
Robert F Wolff (2)
Marie E Westwood (2)
Fül?p J Scheibler (1)
Christoph Schürmann (1)
Brigitta G Baumert (4)
Stefan Sauerland (1)
Jos Kleijnen (2) (3) - 关键词：Positron emission tomography ; Computed tomography ; Staging ; Recurrence ; Esophageal neoplasms ; Systematic review
- 刊名：Systematic Reviews
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：1
- 期：1
- 全文大小：401KB
- 参考文献：1. National Collaborating Centre for Cancer: / Guidance on Cancer Services: Improving Outcomes for People with Skin Tumours including Melanoma; The Manual, Vol. 2009. National Institute for Health and Clinical Excellence, London; 2006.
2. Garbe C, Peris K, Hauschild A, Saiag P, Midddleton M, Spatz A, Grob JJ, Malvehy J: Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. / Eur J Cancer Clin Oncol 2010, 46:270-83.
3. Diagnosis and Treatment of Melanoma: European Consensus-based Interdisciplinary Guideline http://www.ecco-org.eu/binarydata.aspx?type=doc/diagnosis_and_treatment_of_melanoma.pdf
4. Dummer R, Hauschild A, Pentheroudakis G: Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. / Ann Oncol 2009,20(Suppl 4):129-31.
5. Saiag P, Bosquet L, Guillot B, Verola O, Avril MF, Bailly C, Cupissol D, Dalac S, Danino A, Dréno B, Grob JJ, Leccia MT, Renaud-Vilmer C, Négrier S, de Dermatologie SF: Management of adult patients with cutaneous melanoma without distant metastasis: 2005 update of the French standards, options and recommendations guidelines; summary report. / Eur J Dermatol 2007, 17:325-31.
6. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, MacKie R, Nathan P, Peach H, Powell B, Walker C, British Association of Dermatologists Clinical Standards Unit: Revised U.K. guidelines for the management of cutaneous melanoma. / Br J Dermatol 2010, 163:238-56. CrossRef
7. Allgemeine Methoden: Version 4.0 https://www.iqwig.de/download/IQWiG_Entwurf_Methoden_Version_4-0.pdf
8. Positronenemissionstomographie (PET und PET/CT) bei malignen Melanom https://www.iqwig.de/download/D06-01F_Abschlussbericht_PET_und_PET-CT_bei_malignem_Melanom.pdf
9. Oxman AD, Guyatt GH: Validation of an index of the quality of review articles. / J Clin Epidemiol 1991, 44:1271-278. CrossRef
10. Oxman AD, Guyatt GH, Singer J, Goldsmith CH, Hutchison BG, Milner RA, Streiner DL: Agreement among reviewers of review articles. / J Clin Epidemiol 1991, 44:91-8. CrossRef
11. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. / BMC Med Res Methodol 2003, 3:25. CrossRef
12. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. / Ann Intern Med 2011, 155:529-36.
13. Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binominal. / Biometrika 1934, 26:404-13. CrossRef
14. Jiménez-Requena F, Delgado-Bolton RC, Fernandez-Perez C, Gambhir SS, Schwimmer J, Perez-Vazquez JM, Carreras-Delgado JL: Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma. / Eur J Nucl Med Mol Imaging 2010, 37:284-00. CrossRef
15. Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander Borght T: Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. / Radiology 2008, 249:836-44. CrossRef
16. Mijnhout GS, Hoekstra OS, Van Tulder MW, Teule GJ, Deville WL: Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. / Cancer 2001, 91:1530-542. CrossRef
17. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN: Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. / J Natl Cancer Inst 2011, 103:129-42. CrossRef
18. Acland KM, Healy C, Calonje E, O’Doherty M, Nunan T, Page C, Higgins E, Russell-Jones R: Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. / J Clin Oncol 2001, 19:2674-678.
19. Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P: Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. / Oncologist 2002, 7:271-78. CrossRef
20. Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, Jurecka W, Steiner A: Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. / Melanoma Res 2004, 14:141-45. CrossRef
21. Klein M, Freedman N, Lotem M, Marciano R, Moshe S, Gimon Z, Chisin R: Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: a pilot study. / Nuklearmedizin 2000, 39:56-1.
22. Rinne D, Baum RP, Hor G, Kaufmann R: Primary staging and follow-up of high risk melanoma patients with whole-body 18 F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. / Cancer 1998, 82:1664-671. CrossRef
23. Singh B, Ezziddin S, Palmedo H, Reinhardt M, Strunk H, Tuting T, Biersack HJ, Ahmadzadehfar H: Preoperative 18 F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. / Melanoma Res 2008, 18:346-52. CrossRef
24. Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S, Sorensen SS, Drzewiecki KT, Hojgaard L, Friberg L: Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. / Eur J Nucl Med 2000, 27:70-5. CrossRef
25. Hafner J, Schmid MH, Kempf W, Burg G, Kunzi W, Meuli-Simmen C, Neff P, Meyer V, Mihic D, Garzoli E, Jungius KP, Seifert B, Dummer R, Steinert H: Baseline staging in cutaneous malignant melanoma. / Br J Dermatol 2004, 150:677-86. CrossRef
26. Vereecken P, Laporte M, Petein M, Steels E, Heenen M: Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. / J Eur Acad Dermatol Venereol 2005, 19:66-3. CrossRef
27. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, Cascinelli N, Bombardieri E: Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. / J Nucl Med 2000, 41:1491-494.
28. Maubec E, Lumbroso J, Masson F, Suciu V, Kolb F, Mamelle G, Cavalcanti A, Boitier F, Spatz A, Aupérin A, Leboulleux S, Avril MF: F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. / Melanoma Res 2007, 17:147-54. CrossRef
29. Reinhardt MJ, Kensy J, Frohmann JP, Willkomm P, Reinhold U, Grunwald F, Biersack HJ, Bender H: Value of tumour marker S-100B in melanoma patients: a comparison to 18 F-FDG PET and clinical data. / Nuklearmedizin 2002, 41:143-47.
30. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL: Meta-analysis of the performance of 18 F-FDG PET in primary tumor detection in unknown primary tumors. / J Nucl Med 2003, 44:1301-314.
31. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. / JAMA 2001, 285:914-24. CrossRef
32. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS: A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. / J Nucl Med 2000, 41:1177-189.
33. Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, Phelps ME, Czernin J, Gambhir SS: A review of the literature for whole-body FDG PET in the management of patients with melanoma. / Q J Nucl Med 2000, 44:153-67.
34. Aukema TS, Valdes Olmos RA, Wouters MWJM, Klop WMC, Kroon BBR, Vogel WV, Nieweg OE: Utility of preoperative 18 F-FDG PET/CT and brain MRI in melanoma patients with palpable Lymph node metastases. / Ann Surg Oncol 2010, 17:2773-778. CrossRef
35. Bastiaannet E, Wobbes T, Hoekstra OS, Van der Jagt EJ, Brouwers AH, Koelemij R, De Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ: Prospective comparison of [ 18 F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. / J Clin Oncol 2009, 27:4774-780. CrossRef
36. Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steinert HC: High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. / Radiology 2007, 244:566-74. CrossRef
37. Veit-Haibach P, Vogt FM, Jablonka R, Kuehl H, Bockisch A, Beyer T, Dahmen G, Rosenbaum S, Antoch G: Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. / Eur J Nucl Med Mol Imaging 2009, 36:910-18. CrossRef
38. Brady MS, Akhurst T, Spanknebel K, Hilton S, Gonen M, Patel A, Larson S: Utility of preoperative [18]F fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. / Ann Surg Oncol 2006, 13:525-32. CrossRef
39. Fryback DG, Thornbury JR: The efficacy of diagnostic imaging. / Med Decis Making 1991, 11:88-4. CrossRef
40. Verfahrensordnung des Gemeinsamen Bundesausschusses http://www.g-ba.de/downloads/62-492-634/VerfO_2012-06-21.pdf
41. K?bberling J, Trampisch HJ, Windeler J: Memorandum for the evaluation of diagnostic measures. / Clin Chem Clin Biochem 1990, 28:873-79.
42. Updating QUADAS: Evidence to Inform the Development of QUADAS-2 http://www.bris.ac.uk/quadas/resources/quadas2reportv4.pdf
43. Altman DG, Bland JM: Statistics notes: units of analysis. / BMJ 1997, 314:1874. CrossRef
44. Kokoska MS, Olson G, Kelemen PR, Fosko S, Dunphy F, Lowe VJ, Stack BC Jr: The use of lymphoscintigraphy and PET in the management of head and neck melanoma. / Otolaryngol Head Neck Surg 2001, 125:213-20. CrossRef
45. Longo MI, Lazaro P, Bueno C, Carreras JL, Montz R: Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. / Dermatol Surg 2003, 29:245-48. CrossRef - 作者单位：Milly A Schr?er-Günther (1)
Robert F Wolff (2)
Marie E Westwood (2)
Fül?p J Scheibler (1)
Christoph Schürmann (1)
Brigitta G Baumert (4)
Stefan Sauerland (1)
Jos Kleijnen (2) (3)
1. Institute for Quality and Efficiency in Health Care, Im Mediapark 8, Cologne, 50670, Germany
2. Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park Riccall Road, Escrick, York, YO19 6FD, UK
4. Department of Radiation–Oncology (MAASTRO), GROW (School for Oncology & Developmental Biology), Maastricht University Medical Center, P.O. Box 616, Maastricht, MD, 6200, the Netherlands
3. School for Public Health and Primary Care (CAPHRI), Maastricht University, Universiteitssingel 40, Maastricht, ER, 6229, the Netherlands - ISSN：2046-4053
文摘
Purpose The aim of this systematic review was to systematically assess the potential patient-relevant benefit (primary aim) and diagnostic and prognostic accuracy (secondary aim) of positron emission tomography (PET) and PET/computed tomography (CT) in primary staging of malignant melanoma. This systematic review updates the previous evidence for PET(/CT) in malignant melanoma. Materials and methods For the first aim, randomized controlled trials (RCTs) investigating patient-relevant outcomes and comparing PET and PET(/CT) with each other or with conventional imaging were considered. For the secondary aim, a review of reviews was conducted, which was amended by an update search for primary studies. MEDLINE, EMBASE and four databases of the Cochrane Library were searched. The risk of bias was assessed using a modified QUADAS tool. Results No RCTs investigating the patient-relevant benefit of PET(/CT) and no prognostic accuracy studies were found. Seventeen diagnostic accuracy studies of varying quality were identified. For patients with American Joint Committee on Cancer (AJCC) stages I and II, sensitivity mostly ranged from 0 to 67%. Specificity ranged from 77 to 100%. For AJCC stages III and IV, sensitivity ranged from 68 to 87% and specificity from 92 to 98%. Conclusion There is currently no evidence of a patient-relevant benefit of PET(/CT) in the primary staging of malignant melanoma. RCTs investigating patient-relevant outcomes are therefore required. The diagnostic accuracy of PET(/CT) appears to increase with higher AJCC stages.